Calcipotriene Patent Expiration
Calcipotriene was first introduced by Leo Pharma As
Calcipotriene Patents
Given below is the list of patents protecting Calcipotriene, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Sorilux | US8263580 | Vitamin formulation | May 07, 2028 | Mayne Pharma |
| Sorilux | US8269128 | Vacuum switch tube |
May 26, 2026
(Expired) | Mayne Pharma |
| Sorilux | US8629128 | Vitamin formulation |
May 26, 2026
(Expired) | Mayne Pharma |
| Dovonex | US5763426 | Crystalline form of a vitamin D analogue |
Jun 09, 2015
(Expired) | Leo Pharm |
| Dovonex | US5763426 | Crystalline form of a vitamin D analogue |
Jun 09, 2015
(Expired) | Leo Pharma As |
| Dovonex | USRE39706 | Crystalline form of a vitamin D analogue |
Jun 09, 2015
(Expired) | Leo Pharm |
| Dovonex | USRE39706 | Crystalline form of a vitamin D analogue |
Jun 09, 2015
(Expired) | Leo Pharma As |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or
decrease the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that
drug. Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in
the patent process of
the drug which can give an idea of how early a drug's generic could be available. The next
section provides a list
of recent legal activities on Calcipotriene's patents.
Latest Legal Activities on Calcipotriene's Patents
Given below is the list recent legal activities going on the following patents of Calcipotriene.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 20 Jun, 2025 | US8629128 |
| Payment of Maintenance Fee, 12th Yr, Small Entity | 04 Mar, 2024 | US8269128 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 21 Feb, 2024 | US8263580 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 23 Jun, 2021 | US8629128 |
| Payment of Maintenance Fee, 8th Yr, Small Entity | 16 Mar, 2020 | US8269128 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 18 Feb, 2020 | US8263580 |
| Recordation of Patent Grant Mailed Critical
| 14 Jan, 2014 | US8629128 |
| Patent Issue Date Used in PTA Calculation Critical
| 14 Jan, 2014 | US8629128 |
| Email Notification Critical
| 25 Dec, 2013 | US8629128 |
| Issue Notification Mailed Critical
| 24 Dec, 2013 | US8629128 |
Calcipotriene's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Calcipotriene:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| Intralesional 5-Fluorouracil (5FU), Topical Calcipotriene Treatment for SCC | Melissa Pugliano-Mauro | NA |
RECRUITING
(May 1, 2026)
| PHASE1 |
| A Pilot Clinical Trial Comparing Topical Fluorouracil to Fluorouracil Plus Calcipotriene Field Treatments in Patients With Multiple Actinic Keratoses | M.D. Anderson Cancer Center | NA |
RECRUITING
(Apr 1, 2026)
| PHASE3 |